A UGT1A1*28 and*6 genotype-directed phase i dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 6, 2013, Pages 1609-1617

  Kim, Kyu Pyo ^a   Kim, Ho Sook ^b   Sym, Sun Jin ^c   Bae, Kyun Seop ^a   Hong, Yong Sang ^a   Chang, Heung Moon ^a   Lee, Jae Lyun ^a   Kang, Yoon Koo ^a   Lee, Jung Shin ^a   Shin, Jae Gook ^b   Kim, Tae Won ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c Gachon University   (South Korea)

Author keywords

Capecitabine; Colorectal cancer; Irinotecan; Polymorphism; UGT1A1

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CAPECITABINE PLUS IRINOTECAN; DRUG METABOLITE; FIRTECAN; FIRTECAN GLUCURONIDE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A1 28; GLUCURONOSYLTRANSFERASE 1A1 6; IRINOTECAN; UNCLASSIFIED DRUG; BILIRUBIN URIDINE DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; BILIRUBIN URIDINE-DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; CAMPTOTHECIN; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; GLUCURONOSYLTRANSFERASE;

ABDOMINAL PAIN; ADULT; ALLELE; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG GLUCURONIDATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ETHNIC GROUP; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; GENOTYPE; HAND FOOT SYNDROME; HUMAN; KOREAN; LEUKOPENIA; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM TOLERATED DOSE; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; STOMATITIS; THROMBOCYTOPENIA; ADOLESCENT; AGED; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; PATHOLOGY; SOUTH KOREA;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; GLUCURONOSYLTRANSFERASE; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; REPUBLIC OF KOREA; YOUNG ADULT;

MLCS; MLOWN;

EID: 84878623032     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2161-6     Document Type: Article

References (38)

1. Akaba K, Kimura T, Sasaki A, Tanabe S, Ikegami T, Hashimoto M, Umeda H, Yoshida H, Umetsu K, Chiba H, Yuasa I, Hayasaka K (1998) Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate- glucuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese. Biochem Mol Biol Int 46:21-26
2. Akiyama Y, Fujita K, Nagashima F, Yamamoto W, Endo H, Sunakawa Y, Yamashita K, Ishida H, Mizuno K, Araki K, Ichikawa W, Miya T, Narabayashi M, Kawara K, Sugiyama M, Hirose T, Ando Y, Sasaki Y (2008) Genetic testing for UGT1A1*28 and*6 in Japanese patients who receive irinotecan chemotherapy. Ann Oncol 19:2089-2090
3. Araki K, Fujita K, Ando Y, Nagashima F, Yamamoto W, Endo H, Miya T, Kodama K, Narabayashi M, Sasaki Y (2006) Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Cancer Sci 97:1255-1259
4. Cho HJ, Park YS, Kang WK, Kim JW, Lee SY (2007) Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity. Ther Drug Monit 29:190-196
5. Davies JM, Goldberg RM (2008) First-line therapeutic strategies in metastatic colorectal cancer. Oncology (Williston Park) 22:1470-1479
6. de Jong FA, de Jonge MJ, Verweij J, Mathijssen RH (2006) Role of pharmacogenetics in irinotecan therapy. Cancer Lett 234:90-106
7. Di Paolo A, Bocci G, Polillo M, Del Re M, Di Desidero T, Lastella M, Danesi R (2011) Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity. Curr Drug Metab 12:932-943
8. Esaki T, Satoh T, Ura T, Tsujinaka T, Sasaki Y, Yamazaki K, Yamada Y, Ishizuka N, Hyodo I, Sakata Y (2009) A prospective PGx and PK/PD dose-finding study of irinotecan based on UGT1A1*6 and*28 genotyping (UGT0601). J Clin Oncol 27:abstr e14560
9. Falandry C, You B, Milano G, Chatelut E, Rebischung C, Glehen O, Mille D, Delord J, Lledo G, Trillet-Lenoir V, Freyer G (2007) Individual genotyping to optimize chemotherapy in metastatic colorectal cancer (MCRC): the COLOGEN trial. J Clin Oncol 25(18S):2510
10. Farhat FS, Kattan J, Ghosn MG (2010) Role of capecitabine and irinotecan combination therapy in advanced or metastatic gastric cancer. Expert Rev Anticancer Ther 10:541-548
11. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B, Barrueco J (2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25:4779-4786
12. Fujita K, Ando Y, Nagashima F, Yamamoto W, Eodo H, Araki K, Kodama K, Miya T, Narabayashi M, Sasaki Y (2007) Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer. Cancer Chemother Pharmacol 60:515-522
13. Garcia-Alfonso P, Munoz-Martin A, Mendez-Urena M, Quiben-Pereira R, Gonzalez-Flores E, Perez-Manga G (2009) Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group. Br J Cancer 101:1039-1043
14. Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, Jang IJ, Lee DH, Lee JS (2006) Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 24:2237-2244
15. Hazama S, Nagashima A, Kondo H, Yoshida S, Shimizu R, Araki A, Yoshino S, Okayama N, Hinoda Y, Oka M (2010) Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1*28 polymorphism. Cancer Sci 101:722-727
16. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL (2007) UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 99:1290-1295
17. Hu ZY, Yu Q, Pei Q, Guo C (2010) Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk. Clin Cancer Res 16:3832-3842
18. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramirez J, Rudin CM, Vokes EE, Ratain MJ (2004) Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22:1382-1388
19. Ishida H, Fujita K, Akiyama Y, Sunakawa Y, Yamashita K, Mizuno K, Miwa K, Kawara K, Ichikawa W, Ando Y, Saji S, Sasaki Y (2011) Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1 genotype and physical background is feasible in Japanese patients with advanced colorectal cancer. Jpn J Clin Oncol 41:617-623
20. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL, Ratain MJ (1998) Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101:847-854
21. Jada SR, Lim R, Wong CI, Shu X, Lee SC, Zhou Q, Goh BC, Chowbay B (2007) Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C > A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer Sci 98:1461-1467
22. Kohne CH, De Greve J, Hartmann JT, Lang I, Vergauwe P, Becker K, Braumann D, Joosens E, Muller L, Janssens J, Bokemeyer C, Reimer P, Link H, Spath-Schwalbe E, Wilke HJ, Bleiberg H, Van Den Brande J, Debois M, Bethe U, Van Cutsem E (2008) Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol 19:920-926
23. Marcuello E, Altes A, Menoyo A, Del Rio E, Gomez-Pardo M, Baiget M (2004) UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 91:678-682
24. Marcuello E, Paez D, Pare L, Salazar J, Sebio A, del Rio E, Baiget M (2011) A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. Br J Cancer 105:53-57
25. Marsh S, Hoskins JM (2010) Irinotecan pharmacogenomics. Pharmacogenomics 11:1003-1010
26. Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K, Kaniwa N, Sawada J, Hamaguchi T, Yamamoto N, Shirao K, Yamada Y, Ohmatsu H, Kubota K, Yoshida T, Ohtsu A, Saijo N (2007) Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and*28. Pharmacogenet Genomics 17:497-504
27. Sai K, Saeki M, Saito Y, Ozawa S, Katori N, Jinno H, Hasegawa R, Kaniwa N, Sawada J, Komamura K, Ueno K, Kamakura S, Kitakaze M, Kitamura Y, Kamatani N, Minami H, Ohtsu A, Shirao K, Yoshida T, Saijo N (2004) UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther 75:501-515
28. Satoh T, Ura T, Yamada Y, Yamazaki K, Tsujinaka T, Munakata M, Nishina T, Okamura S, Esaki T, Sasaki Y, Koizumi W, Kakeji Y, Ishizuka N, Hyodo I, Sakata Y (2011) Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms. Cancer Sci 102:1868-1873
29. Shimoyama S (2010) Pharmacogenetics of irinotecan: an ethnicity-based prediction of irinotecan adverse events. World J Gastrointest Surg 2:14-21
30. Shulman K, Cohen I, Barnett-Griness O, Kuten A, Gruber SB, Lejbkowicz F, Rennert G (2011) Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients. Cancer 117:3156-3162
31. Skof E, Rebersek M, Hlebanja Z, Ocvirk J (2009) Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial. BMC Cancer 9:120
32. Slatter JG, Schaaf LJ, Sams JP, Feenstra KL, Johnson MG, Bombardt PA, Cathcart KS, Verburg MT, Pearson LK, Compton LD, Miller LL, Baker DS, Pesheck CV, Lord RS 3rd (2000) Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. Drug Metab Dispos 28:423-433
33. Sukumaran S, Pavlakis N, Pittman KB, Patterson K, Price TJ (2009) Capecitabine and irinotecan (XELIRI) in first-line treatment of metastatic colorectal cancer (mCRC): a systematic review of controlled clinical trials. J Clin Oncol 27:e15100
34. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
35. Toffoli G, Cecchin E, Gasparini G, D'Andrea M, Azzarello G, Basso U, Mini E, Pessa S, De Mattia E, Lo Re G, Buonadonna A, Nobili S, De Paoli P, Innocenti F (2010) Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 28:866-871
36. Van Cutsem E, Dirix L, Van Laethem JL, Van Belle S, Borner M, Gonzalez Baron M, Roth A, Morant R, Joosens E, Gruia G, Sibaud D, Bleiberg H (2005) Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study. Br J Cancer 92:1055-1062
37. Ychou M, Raoul JL, Desseigne F, Borel C, Caroli-Bosc FX, Jacob JH, Seitz JF, Kramar A, Hua A, Lefebvre P, Couteau C, Merrouche Y (2002) High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer. Cancer Chemother Pharmacol 50:383-391
38. Yea SS, Lee SS, Kim WY, Liu KH, Kim H, Shon JH, Cha IJ, Shin JG (2008) Genetic variations and haplotypes of UDP-glucuronosyltransferase 1A locus in a Korean population. Ther Drug Monit 30:23-34